Many effective treatments for multiple myeloma exist, but it is currently incurable. This means that even after successful treatment has provided a period of remission or stable disease, myeloma will return. When this happens, it’s called recurrent or relapsed. If the myeloma does not respond to treatment or comes back within 60 days after the last dose of treatment, it is known as refractory. Enter Allogene Therapeutics, a clinical-stage biotech that develops allogeneic CAR therapies for cancer including relapsed/refractory multiple myeloma.